-
Media Release
Multimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media Release
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media Release
Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
-
Media Release
Novartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
-
Media Release
FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media Release
FDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media Release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
-
Media Release
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
-
Media Release
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media Release
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
-
Media Release
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
-
Media Release
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL